Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.48 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | KRAS | P01116 | 7/20 | 0.39 |
| ▸ | KDR | P35968 | 7/20 | 0.39 |
| ▸ | ARAF | P10398 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | CSK | P41240 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055255 | 0.93 | RAF1 (0.47) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5054980 | 0.92 | BRAF (0.51) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5055227 | 0.92 | BRAF (0.47) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5054582 | 0.91 | BRAF (0.40) | RAF1BRAFKRASKDRABL1 | |
| SCHEMBL5056511 | 0.91 | RAF1 (0.51) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5055052 | 0.88 | RAF1 (0.49) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5055011 | 0.87 | RAF1 (0.49) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5055034 | 0.84 | BRAF (0.38) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL5054686 | 0.84 | BRAF (0.47) | RAF1BRAFKRASKDRARAF | |
| SCHEMBL5052360 | 0.83 | BRAF (0.41) | RAF1BRAFKRASKDRARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | RAF1 55/4885BRAF 2/4885KRAS 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.